Kidney

ProKidney Announces Online Publication of Trial Design for Phase II Multicenter Clinical Trial of REACT® Autologous Cell Therapy for Treatment of Chronic Kidney Disease

Retrieved on: 
Thursday, January 27, 2022 - 1:00pm

The paper, titled Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design, was published online and will appear in a future print edition of the Journal (DOI: 10.1159/000520231).

Key Points: 
  • The paper, titled Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design, was published online and will appear in a future print edition of the Journal (DOI: 10.1159/000520231).
  • The study is a prospective, multicenter, randomized control, open-label Phase II clinical trial that enrolled a total of 83 subjects ages 30-80 with Type 2 diabetic kidney disease.
  • Following a kidney biopsy, subjects were randomized 1:1 to receive either active treatment with REACT or optimized standard of care.
  • ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research.

American Kidney Fund Strongly Supports Passage of Living Donor Protections in Virginia

Retrieved on: 
Wednesday, January 26, 2022 - 1:46pm

ROCKVILLE, Md., Jan. 26, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announces strong support for the passage of Virginia Senate Bill 271.

Key Points: 
  • ROCKVILLE, Md., Jan. 26, 2022 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today announces strong support for the passage of Virginia Senate Bill 271.
  • If this bill passes, Virginia will join the 20 states that now provide living organ donors with these important protections, thanks to AKFs efforts.
  • AKFs State of the States: Living Donor Protection Report Card measures seven types of legislation states should enact to provide protections for living organ donors and encourage living donations.
  • The American Kidney Fund (AKF) fights kidney disease on all fronts as the nations leading kidney nonprofit.

Children’s Hospital Los Angeles Awarded $8.3 Million to Study Long-Term Effects of COVID in Children

Retrieved on: 
Wednesday, January 26, 2022 - 8:00pm

Childrens Hospital Los Angeles is one of the few hospitals in California with a program dedicated to long COVID recovery care in children and young adults.

Key Points: 
  • Childrens Hospital Los Angeles is one of the few hospitals in California with a program dedicated to long COVID recovery care in children and young adults.
  • The study also will focus on two other post-COVID/PASC conditions Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID vaccine-associated myocarditis .
  • Founded in 1901, Children's Hospital Los Angeles is the highest-ranked hospital in California and fifth in the nation on the prestigious U.S. News & World Report Honor Roll of Best Childrens Hospitals.
  • The hospital also operates the largest pediatric residency training program at a freestanding childrens hospital in the Western United States.

The Worldwide Hemostats Industry is Expected to Reach $2.6+ Billion in 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 25, 2022 - 12:11pm

Increased focus on blood loss management will also lead to the growth of the Hemostats market during the given forecast period.

Key Points: 
  • Increased focus on blood loss management will also lead to the growth of the Hemostats market during the given forecast period.
  • Growth in the number of hospitals and surgical centers across the globe will further require Hemostats for blood loss management, thus, boosting the market for Hemostats.
  • The growing number of accidents leading to the surgery requirement will also support the Hemostats market.
  • The market is expected to surge in the coming years, due to the rising number of accidents, worldwide.

DiaMedica Therapeutics to Present Research at International Stroke Conference

Retrieved on: 
Tuesday, January 25, 2022 - 1:43pm

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 11, 2022.

Key Points: 
  • DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that the Company will be presenting two abstracts at the American Heart Association 2022 International Stroke Conference being held in New Orleans, LA and Virtually from February 9 11, 2022.
  • These abstracts will be presented in person at Poster Hall B2 (Poster Boards CTP16 & CTP17) on Thursday February 10, 2022, from 12:30 PM 01:15 PM.
  • DiaMedica will also be exhibiting at the conference located in the main hall at booth 111.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution of CAP-1002 for the Treatment* of Duchenne Muscular Dystrophy in US

Retrieved on: 
Tuesday, January 25, 2022 - 7:58pm

The original news release was issued by Nippon Shinyaku Co., Ltd., the parent company of NS Pharma on January 25, 2022 (Japan standard time).

Key Points: 
  • The original news release was issued by Nippon Shinyaku Co., Ltd., the parent company of NS Pharma on January 25, 2022 (Japan standard time).
  • Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan, President: Toru Nakai) announced today that Nippon Shinyaku and Capricor Therapeutics (Headquarters: California, USA, CEO: Linda Marbn, NASDAQ: CAPR) have entered into an exclusive distribution agreement for CAP-1002 for the treatment* of Duchenne muscular dystrophy (DMD) in the territory of US.
  • DMD is a progressive muscular dystrophy caused by a deficiency of the dystrophin protein leading to weakness of skeletal, cardiac, and pulmonary muscles.
  • Executing this agreement with Capricor, Nippon Shinyaku aims to contribute further to the treatment for patients suffering from DMD.

Texas Children's Hospital Leads the Nation in Pediatric Transplants

Retrieved on: 
Tuesday, January 25, 2022 - 1:10pm

HOUSTON, Jan. 25, 2022 /PRNewswire/ -- Texas Children's Hospital leads the nation in pediatric transplants, as reported this week by the Organ Procurement & Transplantation Network (OPTN), the country's unique public-private registry for organ matching.

Key Points: 
  • HOUSTON, Jan. 25, 2022 /PRNewswire/ -- Texas Children's Hospital leads the nation in pediatric transplants, as reported this week by the Organ Procurement & Transplantation Network (OPTN), the country's unique public-private registry for organ matching.
  • In 2021, Texas Children's Hospital Transplant Services successfully performed 118 transplants, outpacing all other children's hospitals by more than 30 complex surgeries.
  • "The Texas Children's Hospital Transplant Services team's impressive volume of pediatric transplants is topped only by its success rate," said Dr. Larry H. Hollier, Surgeon-in-Chief and Chair of the Texas Children's Hospital Department of Surgery.
  • The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; and Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston.

BioAegis’ Novel Host-directed Human Protein for Inflammatory Diseases Geared for Growth in 2022

Retrieved on: 
Monday, January 24, 2022 - 8:52pm

Susan Levinson, PhD, Chief Executive Officer of BioAegis Therapeutics stated, With pride in the very significant accomplishments of our team this year, I look forward to an exciting 2022 demonstrating the value of gelsolin treatment to patients with inflammatory conditions.

Key Points: 
  • Susan Levinson, PhD, Chief Executive Officer of BioAegis Therapeutics stated, With pride in the very significant accomplishments of our team this year, I look forward to an exciting 2022 demonstrating the value of gelsolin treatment to patients with inflammatory conditions.
  • BioAegis platform is built upon the recombinant form of plasma gelsolin, a highly conserved abundant human protein in healthy individuals.
  • It holds over 40 patents issued for coverage of infection, inflammatory disease, renal failure, multiple sclerosis and other neurologic diseases.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

William R. Wise, MD, is being recognized by Continental Who's Who as a Distinguished Doctor for medical contributions in the Medical field and his professional excellence at Las Vegas Urology.

Retrieved on: 
Monday, January 24, 2022 - 10:51pm

LAS VEGAS, Jan. 24, 2022 /PRNewswire/ -- William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.

Key Points: 
  • LAS VEGAS, Jan. 24, 2022 /PRNewswire/ -- William R. Wise, MD, has been helping patients in the greater Las Vegas area for more than 34 years.
  • Minimally invasive options are offered at Las Vegas Urology in order to provide same-day procedures, and minimize pain and discomfort.
  • Las Vegas Urology is currently offering video e-visits and telehealth options throughout its eight locations in Nevada.
  • Wise is a member of the American Medical Association, Clark County Medical Society, Las Vegas Urologic Society, and American Urological Association Western Section.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Reata Pharmaceuticals, Inc. (RETA)

Retrieved on: 
Monday, January 24, 2022 - 6:00pm

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
  • If you purchased or otherwise acquired Reata securities during the Class Period, you may move the Court no later than February 18, 2022 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles